Live In Play®
Updated: 13-Apr-23 07:04 ET
TLSA:  Tiziana Life Sciences announces it plans to investigate intranasal foralumab for the treatment of Long COVID  (1.02)
  • The work is supported by foralumab's well-established role in de-activating microglia cells, a key component in the pathogenesis of this disease.
  • Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trln.
  • The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana's first-in-class intranasal foralumab dampens activated microglia.
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.
Send
Chat Icon